2014
DOI: 10.1111/epi.12847
|View full text |Cite
|
Sign up to set email alerts
|

Long‐term outcome in children with infantile spasms treated with vigabatrin: A cohort of 180 patients

Abstract: SUMMARYObjective: Evaluation of efficacy of vigabatrin as the first drug in infants with previously untreated infantile spasms (IS) and reporting the long-term outcome. Methods: We analyzed a cohort of 180 infants with infantile spasms treated with vigabatrin as the first drug. Following initial evaluation and a 48-h basal period for counting the spasms, vigabatrin was administered using the same protocol in all. After 14 days all infants were assessed for therapeutic response (primary outcome). Psychomotor de… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

3
49
0
2

Year Published

2015
2015
2022
2022

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 44 publications
(54 citation statements)
references
References 31 publications
3
49
0
2
Order By: Relevance
“…Other studies have demonstrated improved outcomes with initiation of treatment within 4 weeks of spasms present as well as early response to treatment. 6,[35][36][37][38][39] Cohen et al 37 have reported improved seizure and cognitive outcome with early initiation of ACTH. The majority of these studies have cohorts that are exclusively "cryptogenic children," who have no prior developmental delay and no identifiable etiology.…”
Section: Discussionmentioning
confidence: 99%
“…Other studies have demonstrated improved outcomes with initiation of treatment within 4 weeks of spasms present as well as early response to treatment. 6,[35][36][37][38][39] Cohen et al 37 have reported improved seizure and cognitive outcome with early initiation of ACTH. The majority of these studies have cohorts that are exclusively "cryptogenic children," who have no prior developmental delay and no identifiable etiology.…”
Section: Discussionmentioning
confidence: 99%
“…VGB is currently used as adjuvant therapy for refractory epilepsies, complex partial seizures, secondarily generalized seizures, infantile spasms, and is under active investigation in tuberous sclerosis complex . However, an extensive body of literature suggests that VGB is associated with peripheral visual field defects (pVFD), but others have suggested that VGB ocular toxicity correlates with pre‐existing anomalies, both structural and genetic .…”
Section: Discussionmentioning
confidence: 99%
“…The differences in dosepool size correlations for the S and R isomers in PFC, VC, and less Figure 6 was employed complex. 2,[22][23][24] However, an extensive body of literature suggests that VGB is associated with peripheral visual field defects (pVFD), 25 but others have suggested that VGB ocular toxicity correlates with pre-existing anomalies, both structural and genetic. 26 The occurrence of permanent visual field constriction in patients receiving VGB is 6-7%).…”
Section: Tissue Vgb Enantiomer Pools As a Function Of Dosementioning
confidence: 99%
“…I have read with great interest the article of Djuric et al., “Long‐term outcome in children with infantile spasms treated with vigabatrin: A cohort of 180 patients.”…”
mentioning
confidence: 99%
“… The numbers have been misquoted. In the Discussion “comparing the results of with ACTH‐treated in a Finnish study, 51/88 patients (58%) versus 48/147 (33%) (48% is an error) were seizure‐free, and 48/83 of patients (57.8%) versus 36/147 (24.5%) showed favorable intellectual outcome.” These figures presented in the article of Djuric et al. concerned responders (Table 4) and not the whole group.…”
mentioning
confidence: 99%